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Introduction
Pulmonary arterial hypertension (PAH) is a progressive
disease with poor survival. PAH is classified by the 2009
updated clinical classification of pulmonary hypertension
and a major subgroup is PAH due to congenital heart
disease (CHD) with systemic-to-pulmonary shunt [1]. This
shunting may lead to extensive histological changes in the
distal pulmonary arteries resulting in an irreversible
increase in pulmonary vascular resistance (PVR). The
classification of CHD-PAH includes four categories: (1)
Eisenmenger syndrome, (2) PAH associated with systemic-
to-pulmonary shunts, (3) PAH with small septal defects,
and (4) PAH after corrective cardiac surgery [2]. In these
patients advanced pharmacological therapy should be
considered.
Three classes of advanced therapy for PAH are currently
in use: prostanoids such as epoprostenol, endothelin-1
receptor antagonists such as bosentan, and phosphodiester-
ase 5 inhibitors such as sildenafil [3]. Bosentan has been
shown to improve 6-min walking distance (6MWD) and to
decrease PVR in patients with Eisenmenger syndrome [4].
Anecdotal experience with the phosphodiesterase type-5
inhibitors sildenafil and tadalafil show favourable function-
al and haemodynamic results in patients with CHD-PAH
[5, 6]. We present three patients treated with advanced
pharmacological therapy for CHD-PAH: a patient with
Eisenmenger syndrome receiving standard care, a patient
with atrial septal defect receiving advanced therapy as a
bridge to surgery, and a patient with segmental PAH who
was started on advanced therapy empirically.
Case 1: an Eisenmenger patient
The first case describes a 38-year-old male patient with a
double inlet left ventricle, hypoplastic aortic arch and patent
ductus arteriosus. He was deemed ineligible for a Fontan
circulation and developed PAH in childhood. He was
severely symptomatic (NYHA functional class III-IV) and
could only live a sedentary lifestyle. He had been on the
waiting list for combined heart and lung transplantation for
2 years. He was cyanotic with a peripheral saturation of
80%. His haemoglobin level was 13.4 mmol/L. On
auscultation, normal heart sounds were heard, as well as a
systolic murmur grade II/VI. Trans-thoracic echocardiogra-
phy (TTE) showed a moderate systolic ventricular function,
mild mitral regurgitation, and moderate tricuspid regurgita-
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tion (Fig. 1). His 6MWD was 475 m, and during exercise
his saturation dropped from 80% to 62%
It was decided to initiate bosentan 125 mg twice daily, as
monotherapy. He improved to NYHA functional class II
and his six 6MWD increased from 475 to 500, 517 and
557 m at 1, 2 and 3 years, respectively. His saturation
remained unchanged. Clinically he has improved over the
past 4 years on bosentan monotherapy and is now able to
work 12 h a week. He could be removed from the
transplantation list.
Case 2: advanced therapy as a bridge to atrial septal
defect closure
A 25-year-old female patient was referred to our hospital
because of progressive dyspnoea for 5 months. Her medical
history was unremarkable, and auscultation revealed fixed
splitting of the second heart sound. The ECG showed sinus
tachycardia of 120 beats/min, right heart axis, and tall R
waves in V1 and V2. The chest x-ray showed a dilated right
pulmonary artery and pulmonary trunk. A CT scan was
performed to rule out pulmonary embolism. Pulmonary
embolism was not observed, but the right ventricle and
pulmonary trunk were severely dilated. In addition, an
anomalous connection of the right upper pulmonary vein to
the superior caval vein was found. TTE revealed a small
left ventricle with good systolic function. The right
ventricle was dilated with poor systolic function. The
interventricular septum was flattened during both diastole
and systole, suggesting right-sided pressure overload.
Agitated saline contrast injection revealed shunting from
the right to left atrium, suggestive of an atrial septal defect.
Transoesophageal echocardiogram (TEE) showed a sinus
venosus defect with a right-to-left shunt (Fig. 2). Right
heart catheterisation demonstrated a pulmonary arterial
pressure (PAP) of 89/46 mmHg (mean 55 mmHg) with a
systemic blood pressure of 118/65 mmHg (mean
82 mmHg). PVR was markedly elevated at 680 dynes/
s/cm−5 (8.5 Wood Units). Epoprostenol infusion to
achieve maximal pulmonary vascular dilation did not
result in a reduction of PVR. Her baseline 6MWD was
514 m and saturation dropped from 97% at rest to 78%
during exercise. The working diagnosis at that time was
PAH associated with systemic-to-pulmonary shunt (Group
2). However, given the unusually severe PAH for a patient
with sinus venosus defect at this age, we could not rule
out that the clinical picture was explained by a combina-
tion of idiopathic pulmonary arterial hypertension (IPAH,
formerly called primary pulmonary hypertension) and a
sinus venosus defect.
This patient was treated with combination therapy of
bosentan 125 mg twice daily and sildenafil 20 mg three
times daily. After several weeks of therapy, subjective
improvement was observed. After 3 months of treatment,
repetition of the right heart catheterisation showed that the
PAP had dropped to 62/32 mmHg (mean 42 mmHg) with a
systemic blood pressure of 104/54 mmHg (mean
73 mmHg). In addition, her 6MWD increased from 514 to
640 m, NT-pro-BNP decreased from 1092 to 497 ng/L, and
saturation during exercise increased from 78% to 90%.
Because of the beneficial response to medical therapy, this
patient was planned for closure of the sinus venosus defect
and rerouting of the pulmonary vein flow to the left atrium.
The interatrial septum will be reconstructed with a
fenestrated patch to facilitate complete closure via percuta-
neous intervention at a later stage. This ‘staged’ procedure
was chosen to minimise the risk of acute right-sided heart
failure, which is a life-threatening complication.
Case 3: advanced therapy in a patient with segmental
PAH started empirically
The third case describes a 39-year-old female patient who
presented with shortness of breath. She had a history of
pulmonary atresia, ventricular septal defect and stenosis of
a major aortopulmonary collateral artery (MAPCA) to the
right inferior pulmonary lobe (Fig. 3). In childhood she had
initially been palliated with a left-sided Blalock-Taussig
shunt to supply pulmonary blood flow, and later with a
central Goretex shunt. New cardiac evaluation followed in
adolescence. At that time further surgical repair was not
indicated, because of her stable cardiac situation and the
risk of complications associated with a reoperation. The
pulmonary lobes supplied by the aorta-pulmonary shunt or
the non-stenosed MAPCAs experienced a systemic blood
pressure and developed PAH, whereas the right inferior
Fig. 1 Eisenmenger patient in case 1. Transthoracic echocardiogram
demonstrating double inlet left ventricle
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lobe supplied by the stenosed MAPCA experienced a
relatively normal PAP and as a consequence did not
develop PAH. The term segmental PAH has been suggested
to describe this situation. She was cyanotic with a
peripheral saturation of 81%. No pathological murmurs
were heard at auscultation. Her NT-pro-BNP was 419 ng/L.
Echocardiographically, her right and left ventricular systolic
function were good. Her 6MWD was 462 m and saturation
dropped from 81% to 65% at exercise.
Because of her shortness of breath, it was decided to
treat this patient empirically with bosentan 125 mg twice
daily as monotherapy. After initiation, clinical improve-
ment was observed. Her 6MWD increased from 462 to
478, 502 and 513 m at 1, 2 and 3 years respectively.
After 3 years of treatment saturation at rest increased
to 85%, and NT-pro-BNP decreased to 334 ng/L.
Clinically she improved to mild shortness of breath.




Anomalous connection of the right upper
pulmonary vein to the superior caval vein
Anomalous connection of the right upper
pulmonary vein to the superior caval vein
Sinus venosus
atrial septal defect
Fig. 2 Sinus venosus atrial septal defect in case 2. a Cardiac computed tomography scan, b Transoesophageal echocardiogram
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Discussion
We describe three adults where advanced pharmacological
therapy for CHD-PAH was prescribed in different clinical
settings. The first patient, diagnosed with Eisenmenger
syndrome, was treated according to current guidelines [7].
In the second patient, therapy was started more aggressively
as a bridge to atrial septal defect closure. The third patient
with segmental PAH was started on advanced therapy
empirically.
Presentation with Eisenmenger syndrome, as in the first
patient, has a negative impact on survival. Eisenmenger
syndrome patients are highly symptomatic, and require
major lifestyle adjustments due to limited functional
capacity. Quality of life is diminished and pregnancy is
strictly contraindicated [8]. In our extended experience with
a nationwide standardised protocol on advanced treatment
in CHD-PAH, a prolonged beneficial effect of bosentan
treatment on 6MWD, echocardiographic stroke volume and
quality of life in patients with Eisenmenger syndrome has
been shown [9]. In patients with additional Down syndrome
stabilisation was seen [9]. The 6MWD is associated with
clinical outcome and prognosis [10]. In the second patient
optimisation with advanced therapy led to eligibility for
surgical closure. The decision to proceed with surgery was
made, regardless of the persistent high mean PAP, on the
basis of reversibility in PVR after 3 months of advanced
medical treatment. Patients with septal defects initially
ineligible for cardiac surgery due to severe PAH could
benefit from advanced therapy as a bridge to surgical
intervention. Patients with segmental PAH, such as our
patient in case three, are rare. Segmental PAH is often due
to post-surgical pulmonary artery stenosis, resulting in local
differences in pulmonary artery pressure and severity of the
pathophysiological changes in the pulmonary circulation.
Our group has reported on several cases with segmental
PAH demonstrating improvement of NYHA functional
class and exercise capacity after 12 months of bosentan
treatment [11].
Also in other patient categories, evidence on beneficial
effect of advanced therapy is increasing. In NYHA
functional class II PAH patients, short-term efficacy of
bosentan has been demonstrated [12]. However, this study
included only 16 patients with CHD-PAH.
Another group of patients who might benefit from
advanced therapy are those with a Fontan circulation. In
Fontan patients’ plasma endothelin-1 level has been shown
to be elevated [13]. Endothelin-1 induces pulmonary
vasoconstriction, and increases PVR. Low PVR is crucial
for a well-functioning Fontan circulation, and endothelin-1
receptor antagonists might therefore contribute to improve-
ment of clinical status in these patients. We are currently
performing a prospective randomised trial on bosentan in
Fontan patients; the results are expected in spring 2012
[14].
Finally, advanced therapy might be useful in CHD
patients who undergo cardiac surgery, who tend to have a
decline in right ventricular function [15]. Treatment with an
endothelin-1 receptor antagonist might reduce perioperative
pulmonary vasoconstriction induced by the endothelin-1
release initiated by the cardiopulmonary bypass [16]. In a
small study, perioperative treatment with a selective
endothelin-1 receptor antagonist led to a significant
decrease in PVR compared with the control group [17].
However, trials are needed to confirm this hypothesis and to
show clinical benefit in CHD patients. In our centre we are
A B
Posterior view Anterior view
Fig. 3 Segmental pulmonary
arterial hypertension in case 3.
a Magnetic resonance angiogra-
phy demonstrating left inferior
MAPCA stenosis, b Schematic
drawing
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currently evaluating the effect of bosentan on perioperative
right ventricular function prospectively.
Conclusion
CHD-PAH remains a severe disease, leading to reduced quality
of life and cardiac complications including right ventricular
failure, arrhythmias and premature death. Our cases demon-
strate the variety of indications in which advanced therapy is
justified. Research is warranted in CHD patients with elevated
endothelin-1 levels, who are at risk of increase in pulmonary
artery pressure, to determine whether these patients benefit of
advanced therapy.
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